{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:28:54Z","timestamp":1790677734445,"version":"4.1.0"},"reference-count":87,"publisher":"Elsevier BV","issue":"2-3","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.schres.2013.07.026","type":"journal-article","created":{"date-parts":[[2013,8,9]],"date-time":"2013-08-09T18:54:59Z","timestamp":1376074499000},"page":"346-352","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":85,"title":["Pharmacological approaches to treating negative symptoms: A review of clinical trials"],"prefix":"10.1016","volume":"150","author":[{"given":"Celso","family":"Arango","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Garibaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen R.","family":"Marder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2013.07.026_bb0005","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1016\/j.pnpbp.2008.08.001","article-title":"A 12-week, double-blind, placebo-controlled trial of donepezil adjunctive treatment to risperidone in chronic and stable schizophrenia","volume":"32","author":"Akhondzadeh","year":"2008","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.schres.2013.07.026_bb0010","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/hup.902","article-title":"Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study","volume":"23","author":"Amiri","year":"2008","journal-title":"Hum. psychopharmacol."},{"key":"10.1016\/j.schres.2013.07.026_bb0015","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.eurpsy.2003.10.004","article-title":"The deficit syndrome in schizophrenia: implications for the treatment of negative symptoms","volume":"19","author":"Arango","year":"2004","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.schres.2013.07.026_bb0020","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00213-011-2513-z","article-title":"A placebo-controlled study of the modafinil added to risperidone in chronic schizophrenia","volume":"220","author":"Arbabi","year":"2012","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.schres.2013.07.026_bb0025","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1176\/appi.ajp.163.3.488","article-title":"Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers","volume":"163","author":"Artaloytia","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2013.07.026_bb0030","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0022-3956(93)90036-2","article-title":"Validation of the 16-item Negative Symptom Assessment","volume":"27","author":"Axelrod","year":"1993","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.schres.2013.07.026_bb0035","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1345\/aph.1P008","article-title":"The role of ondansetron in the treatment of schizophrenia","volume":"44","author":"Bennett","year":"2010","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.schres.2013.07.026_bb0040","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.biopsych.2008.03.004","article-title":"N-acetyl cysteine as a glutathione precursor for schizophrenia\u2014a double-blind, randomized, placebo-controlled trial","volume":"64","author":"Berk","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2013.07.026_bb0045","doi-asserted-by":"crossref","first-page":"280","DOI":"10.4088\/JCP.08m04250yel","article-title":"Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study","volume":"71","author":"Bobes","year":"2010","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2013.07.026_bb0050","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00005053-199605000-00005","article-title":"Treatment of negative symptoms in schizophrenia and schizoaffective disorder by selegiline augmentation of antipsychotic medication. A pilot study examining the role of dopamine","volume":"184","author":"Bodkin","year":"1996","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.schres.2013.07.026_bb0055","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1176\/appi.ajp.162.2.388","article-title":"Double-blind, placebo-controlled, multicenter trial of selegiline augmentation of antipsychotic medication to treat negative symptoms in outpatients with schizophrenia","volume":"162","author":"Bodkin","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2013.07.026_bb0060","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1176\/ajp.151.1.20","article-title":"Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia","volume":"151","author":"Breier","year":"1994","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2013.07.026_bb0065","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1176\/appi.ajp.2007.06081358","article-title":"The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments","volume":"164","author":"Buchanan","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2013.07.026_bb0070","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/JCP.0b013e31823f880a","article-title":"Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia","volume":"32","author":"Buchanan","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2013.07.026_bb0075","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/mp.2012.121","article-title":"Another view of the history of antipsychotic drug discovery and development","volume":"17","author":"Carpenter","year":"2012","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.schres.2013.07.026_bb0080","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/BF01276429","article-title":"d-cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label study","volume":"95","author":"Cascella","year":"1994","journal-title":"J. Neural transm."},{"key":"10.1016\/j.schres.2013.07.026_bb0085","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1177\/0269881112444941","article-title":"Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment","volume":"26","author":"Chaudhry","year":"2012","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.schres.2013.07.026_bb0090","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/WNF.0b013e31816f2795","article-title":"The effects of galantamine on psychopathology in chronic stable schizophrenia","volume":"32","author":"Conley","year":"2009","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.schres.2013.07.026_bb0095","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/schbul\/sbs076","article-title":"NMDA receptor and schizophrenia: a brief history","volume":"38","author":"Coyle","year":"2012","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2013.07.026_bb0100","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1176\/ajp.156.4.610","article-title":"Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group","volume":"156","author":"Danion","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2013.07.026_bb0105","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.pnpbp.2004.05.024","article-title":"N-methyl-D-aspartate antagonists as drug models of schizophrenia: a surprising link to tobacco smoking","volume":"28","author":"Domino","year":"2004","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.schres.2013.07.026_bb0110","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.schres.2004.03.013","article-title":"Effects of D-cycloserine on negative symptoms in schizophrenia","volume":"71","author":"Duncan","year":"2004","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2013.07.026_bb0115","first-page":"1","article-title":"Clozapine versus typical neuroleptic medication for schizophrenia","author":"Essali","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.schres.2013.07.026_bb0120","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1176\/appi.ajp.157.5.826","article-title":"Placebo-controlled trial of glycine added to clozapine in schizophrenia","volume":"157","author":"Evins","year":"2000","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2013.07.026_bb0125","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1176\/appi.ajp.2008.07071135","article-title":"Initial phase 2 trial of a nicotinic agonist in schizophrenia","volume":"165","author":"Freedman","year":"2008","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2013.07.026_bb0130","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.4088\/JCP.08m04683","article-title":"Modafinil for clozapine-treated schizophrenia patients: a double-blind, placebo-controlled pilot trial","volume":"70","author":"Freudenreich","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2013.07.026_bb0155","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1176\/ajp.152.8.1213","article-title":"Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia","volume":"152","author":"Goff","year":"1995","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2013.07.026_bb0160","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1176\/ajp.153.12.1628","article-title":"D-cycloserine added to clozapine for patients with schizophrenia","volume":"153","author":"Goff","year":"1996","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2013.07.026_bb0150","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1001\/archpsyc.56.1.21","article-title":"A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia","volume":"56","author":"Goff","year":"1999","journal-title":"Arch. Gen. Psychiatry"},{"issue":"904","key":"10.1016\/j.schres.2013.07.026_bb0140","first-page":"907","article-title":"Augmentation strategies in the treatment of schizophrenia","volume":"6","author":"Goff","year":"2001","journal-title":"CNS Spectr."},{"key":"10.1016\/j.schres.2013.07.026_bb0145","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s00213-004-2032-2","article-title":"A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients","volume":"179","author":"Goff","year":"2005","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.schres.2013.07.026_bb0135","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.schres.2008.08.012","article-title":"Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study","volume":"106","author":"Goff","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2013.07.026_bb0170","first-page":"731","article-title":"Glycinergic augmentation of NMDA receptor-mediated neurotransmission in the treatment of schizophrenia","volume":"32","author":"Heresco-Levy","year":"1996","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.schres.2013.07.026_bb0165","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0006-3223(03)00707-8","article-title":"High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia","volume":"55","author":"Heresco-Levy","year":"2004","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2013.07.026_bb0175","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1021\/cn400023y","article-title":"Is there a path forward for mGlu(2) positive allosteric modulators for the treatment of schizophrenia?","volume":"4","author":"Hopkins","year":"2013","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.schres.2013.07.026_bb0180","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1126\/science.1077141","article-title":"Medicine. What are the right targets for psychopharmacology?","volume":"299","author":"Hyman","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.schres.2013.07.026_bb0185","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1093\/schbul\/sbs100","article-title":"Twenty-five years of glutamate in schizophrenia: are we there yet?","volume":"38","author":"Javitt","year":"2012","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2013.07.026_bb0190","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1176\/ajp.151.8.1234","article-title":"Amelioration of negative symptoms in schizophrenia by glycine","volume":"151","author":"Javitt","year":"1994","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2013.07.026_bb0195","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/00004714-199912000-00006","article-title":"Deprenyl augmentation for treating negative symptoms of schizophrenia: a double-blind, controlled study","volume":"19","author":"Jungerman","year":"1999","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2013.07.026_bb0200","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2013.07.026_bb0215","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1001\/archpsyc.58.10.965","article-title":"Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison","volume":"58","author":"Kane","year":"2001","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2013.07.026_bb0205","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/JCP.0b013e3181d35d6b","article-title":"Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia","volume":"30","author":"Kane","year":"2010","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2013.07.026_bb0210","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.4088\/JCP.09m05950gry","article-title":"Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study","volume":"71","author":"Kane","year":"2010","journal-title":"The Journal of clinical psychiatry"},{"key":"10.1016\/j.schres.2013.07.026_bb0220","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.schres.2011.11.006","article-title":"Adjunctive armodafinil for negative symptoms in adults with schizophrenia: a double-blind, placebo-controlled study","volume":"135","author":"Kane","year":"2012","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2013.07.026_bb0225","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.schres.2010.05.012","article-title":"High dose D-serine in the treatment of schizophrenia","volume":"121","author":"Kantrowitz","year":"2010","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2013.07.026_bb0230","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2013.07.026_bb0235","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.jpsychires.2013.01.011","article-title":"Granisetron as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study","volume":"47","author":"Khodaie-Ardakani","year":"2013","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.schres.2013.07.026_bb0240","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/JCP.0b013e318218dcd5","article-title":"A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia","volume":"31","author":"Kinon","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2013.07.026_bb0245","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/schbul\/sbj053","article-title":"The NIMH-MATRICS consensus statement on negative symptoms","volume":"32","author":"Kirkpatrick","year":"2006","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2013.07.026_bb0250","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1017\/S1461145709990939","article-title":"A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia","volume":"13","author":"Lane","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2013.07.026_bb0255","doi-asserted-by":"crossref","DOI":"10.1038\/npp.2013.111","article-title":"Adjunctive lisdexamfetamine dimesylate therapy in adult outpatients with predominant negative symptoms of schizophrenia: open-label and randomized-withdrawal phases","author":"Lasser","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.schres.2013.07.026_bb0260","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1600-0447.2006.00887.x","article-title":"The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial","volume":"114","author":"Lecrubier","year":"2006","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2013.07.026_bb0265","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.schres.2013.01.001","article-title":"Effects of adjunctive intranasal oxytocin on olfactory identification and clinical symptoms in schizophrenia: results from a randomized double blind placebo controlled pilot study","volume":"145","author":"Lee","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2013.07.026_bb0270","doi-asserted-by":"crossref","first-page":"138","DOI":"10.4088\/JCP.08m04666yel","article-title":"A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia","volume":"71","author":"Levkovitz","year":"2010","journal-title":"The Journal of clinical psychiatry"},{"key":"10.1016\/j.schres.2013.07.026_bb0275","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/npp.2012.259","article-title":"A Randomized exploratory trial of an alpha-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia","volume":"38","author":"Lieberman","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.schres.2013.07.026_bb0280","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1192\/bjp.170.1.18","article-title":"Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia","volume":"170","author":"Loo","year":"1997","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2013.07.026_bb0290","doi-asserted-by":"crossref","first-page":"538","DOI":"10.4088\/JCP.v58n1205","article-title":"The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials","volume":"58","author":"Marder","year":"1997","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2013.07.026_bb0285","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/schbul\/sbq161","article-title":"Methodological issues in negative symptom trials","volume":"37","author":"Marder","year":"2011","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2013.07.026_bb0295","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1038\/npp.2009.26","article-title":"Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia","volume":"34","author":"Marx","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.schres.2013.07.026_bb0300","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1017\/S1041610205003017","article-title":"Donepezil for negative signs in elderly patients with schizophrenia: an add-on, double-blind, crossover, placebo-controlled study","volume":"18","author":"Mazeh","year":"2006","journal-title":"Int. Psychogeriatr."},{"key":"10.1016\/j.schres.2013.07.026_bb0305","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/npp.2011.181","article-title":"From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment","volume":"37","author":"Moghaddam","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.schres.2013.07.026_bb0310","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.0065-1591.2000.007s021[dash]4.x","article-title":"Amisulpride: a review of its efficacy in schizophrenia","volume":"400","author":"Moller","year":"2000","journal-title":"Acta Psychiatr. Scand. Suppl."},{"key":"10.1016\/j.schres.2013.07.026_bb0315","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s004060170030","article-title":"Amisulpride: efficacy in the management of chronic patients with predominant negative symptoms of schizophrenia","volume":"251","author":"Moller","year":"2001","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.schres.2013.07.026_bb0320","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00213-013-3064-2","article-title":"A placebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophrenia","volume":"228","author":"Noroozian","year":"2013","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.schres.2013.07.026_bb0325","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/nm1632","article-title":"Activation of mGlu2\/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial","volume":"13","author":"Patil","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.schres.2013.07.026_bb0335","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1176\/ajp.156.1.145","article-title":"Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia","volume":"156","author":"Potkin","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2013.07.026_bb0330","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.4088\/JCP.v68n1004","article-title":"Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial","volume":"68","author":"Potkin","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2013.07.026_bb0340","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.schres.2012.01.015","article-title":"Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of CATIE data","volume":"137","author":"Rabinowitz","year":"2012","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2013.07.026_bb0345","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/01.jcp.0000237942.50270.35","article-title":"Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial","volume":"26","author":"Ritsner","year":"2006","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2013.07.026_bb0350","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.4088\/JCP.09m05031yel","article-title":"Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: an 8-week, double-blind, randomized, controlled, 2-center, parallel-group trial","volume":"71","author":"Ritsner","year":"2010","journal-title":"The Journal of clinical psychiatry"},{"key":"10.1016\/j.schres.2013.07.026_bb0355","article-title":"Randomized multicenter investigation of folate plus vitamin B12 supplementation in schizophrenia","volume":"1\u20139","author":"Roffman","year":"2013","journal-title":"JAMA psychiatry"},{"key":"10.1016\/j.schres.2013.07.026_bb0360","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1176\/ajp.156.1.88","article-title":"Impact of clozapine on negative symptoms and on the deficit syndrome in refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia","volume":"156","author":"Rosenheck","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2013.07.026_bb0365","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/00002826-199619050-00008","article-title":"D-cycloserine adjuvant therapy to molindone in the treatment of schizophrenia","volume":"19","author":"Rosse","year":"1996","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.schres.2013.07.026_bb0370","doi-asserted-by":"crossref","first-page":"839","DOI":"10.4088\/JCP.v66n0705","article-title":"Double-blind, placebo-controlled study of modafinil for fatigue and cognition in schizophrenia patients treated with psychotropic medications","volume":"66","author":"Sevy","year":"2005","journal-title":"The Journal of clinical psychiatry"},{"key":"10.1016\/j.schres.2013.07.026_bb0375","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1744-859X-9-27","article-title":"A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia","volume":"9","author":"Shiina","year":"2010","journal-title":"Ann. Gen. psychiatry"},{"key":"10.1016\/j.schres.2013.07.026_bb0385","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1192\/bjp.bp.109.067710","article-title":"Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis","volume":"197","author":"Singh","year":"2010","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2013.07.026_bb0380","article-title":"Acetylcholinesterase inhibitors for schizophrenia","volume":"1","author":"Singh","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.schres.2013.07.026_bb0390","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1192\/bjp.171.6.564","article-title":"One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride v. haloperidol","volume":"171","author":"Speller","year":"1997","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2013.07.026_bb0395","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1001\/archpsyc.60.2.133","article-title":"Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia","volume":"60","author":"Strous","year":"2003","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2013.07.026_bb0400","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.psyneuen.2006.11.002","article-title":"Analysis of clinical symptomatology, extrapyramidal symptoms and neurocognitive dysfunction following dehydroepiandrosterone (DHEA) administration in olanzapine treated schizophrenia patients: a randomized, double-blind placebo controlled trial","volume":"32","author":"Strous","year":"2007","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.schres.2013.07.026_bb0405","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S0006-3223(98)00279-0","article-title":"D-serine added to antipsychotics for the treatment of schizophrenia","volume":"44","author":"Tsai","year":"1998","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2013.07.026_bb0415","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1176\/ajp.156.11.1822","article-title":"D-serine added to clozapine for the treatment of schizophrenia","volume":"156","author":"Tsai","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2013.07.026_bb0410","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.biopsych.2005.06.032","article-title":"D-alanine added to antipsychotics for the treatment of schizophrenia","volume":"59","author":"Tsai","year":"2006","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2013.07.026_bb0420","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0924-977X(12)70475-3","article-title":"Post-hoc analysis of the negative symptom factor score in a proof-of-concept study with the glycine reuptake inhibitor (GRI), bitopertin, in schizophrenia","volume":"22","author":"Umbricht","year":"2012","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2013.07.026_bb0425","doi-asserted-by":"crossref","first-page":"e728","DOI":"10.4088\/JCP.11m07031","article-title":"A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia","volume":"73","author":"Weiser","year":"2012","journal-title":"The Journal of clinical psychiatry"},{"key":"10.1016\/j.schres.2013.07.026_bb0430","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1126\/science.566469","article-title":"Neuroleptic-induced \u201canhedonia\u201d in rats: pimozide blocks reward quality of food","volume":"201","author":"Wise","year":"1978","journal-title":"Science"},{"key":"10.1016\/j.schres.2013.07.026_bb0435","doi-asserted-by":"crossref","first-page":"878","DOI":"10.4088\/JCP.v62n1107","article-title":"A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia","volume":"62","author":"Zhang","year":"2001","journal-title":"The Journal of clinical psychiatry"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996413003708?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996413003708?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:24:17Z","timestamp":1760297057000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996413003708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":87,"journal-issue":{"issue":"2-3","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S0920996413003708"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2013.07.026","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological approaches to treating negative symptoms: A review of clinical trials","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2013.07.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}